Proof-of-Concept Vaccine Prevents Pancreatic Cancer in Mice

The Role of the Immune System in Cancer Prevention

The immune system is essential in combating cancer, as it identifies and eliminates early cancer cells or small tumors before they can develop into more serious health issues. Immunotherapies have emerged as a significant category of cancer treatment, focusing on enhancing the body’s anti-tumor immune response. Cancer vaccines, a specific type of immunotherapy, introduce immune cells to tumor-specific proteins known as tumor antigens. These antigens act as ‘danger signals,’ training the immune system to recognize and target tumor cells that display these proteins.

Prophylactic vs. Therapeutic Cancer Vaccines

Prophylactic cancer vaccines differ from therapeutic ones; they are administered to healthy individuals to prevent cancer before it occurs. These vaccines serve as preventive measures, equipping the immune system to inhibit tumor development effectively. An example is the human papillomavirus (HPV) vaccine, which aims to prevent cervical cancer linked to HPV infection. However, options for preventing non-viral cancers have thus far been limited.

The Challenge of Pancreatic Cancer

Pancreatic cancer is particularly concerning, as it has the lowest survival rate among all cancers, with less than 5% of patients surviving beyond five years. The disease typically develops and spreads slowly, often taking more than a decade from the initial cancer-causing mutation to the appearance of symptoms. This prolonged latency period presents an opportunity for preventive measures against this highly lethal cancer.

Development of a Preventive Vaccine

To address this issue, researchers from Queen Mary University of London and Zhengzhou University in China have developed a proof-of-concept vaccine aimed at preventing pancreatic cancer. Their study, published in the journal Clinical Cancer Research, outlines preclinical findings using a mouse model of the disease.

Vaccine Creation and Testing

The team transformed healthy mouse cells into pancreatic tumor cells by introducing two specific mutations into their DNA. Subsequently, these tumor cells were infected with oncolytic viruses—viruses designed to selectively replicate within and kill tumor cells. Although the infected cells lost their tumor-forming capabilities, they maintained the necessary tumor antigen profile to foster anti-tumor immunity. The infected cell vaccine was administered to mice genetically modified to develop pancreatic cancer, resulting in delayed tumor development and significantly extended survival rates. Notably, the treatment was well-tolerated and demonstrated no toxicity.

Future Directions and Implications

Yaohe Wang, the lead author of the study, emphasized the challenges in developing a preventive vaccine for non-viral cancers due to the scarcity of suitable tumor antigens and effective strategies to stimulate robust anti-tumor immunity. This international collaboration marks a significant step toward creating a prophylactic cancer vaccine specifically for pancreatic cancer.

The findings from this research provide preliminary support for the potential development of personalized cancer vaccines targeting pancreatic cancer. The authors intend to investigate further enhancements to the vaccination regimen and explore combination therapies with other immunotherapy approaches.

References

Lu, S. et al. A Virus-Infected, Reprogrammed Somatic cell-derived Tumor cell (VIReST) vaccination regime can prevent initiation and progression of pancreatic cancer. Clin Cancer Res clincanres.1395.2019 (2019) doi:10.1158/1078-0432.CCR-19-1395.
Mahony, C. J. UK and China research team take first steps towards a vaccine for pancreatic cancer. EurekAlert! (2019).
Image by Tibor Janosi Mozes from Pixabay